Purpose Gallium-68 is a metallic positron emitter with a half-life of 68 min that is ideal for the in vivo use of small molecules, such as [ 68 Ga-DOTA,Tyr 3 ]octreotide, in the diagnostic imaging of somatostatin receptor-positive tumours. In preclinical studies it has shown a striking superiority over its 111 In-labelled congener. The purpose of this study was to evaluate whether third-generation somatostatin-based, radiogallium-labelled peptides show the same superiority. Methods Peptides were synthesised on solid phase. The receptor affinity was determined by in vitro receptor autoradiography. The internalisation rate was studied in AR4-2J and hsst-HEK-transfected cell lines. The pharmacokinetics was studied in a rat xenograft tumour model, AR4-2J. Results All peptides showed high affinities on hsst2, with the highest affinity for the Ga III -complexed peptides. On hsst3 the situation was reversed, with a trend towards lower affinity of the Ga III peptides. A significantly increased internalisation rate was found in sst2-expressing cells for all 67 
Introduction
Peptide receptors with high overexpression on a variety of human tumours are a focus of research in radiopharmacy and nuclear oncology. The prototype is the somatostatin receptor, which has been found to be overexpressed not only on neuroendocrine tumours but also on renal cell carcinoma, small cell lung cancer, breast cancer, prostate cancer and malignant lymphoma [1] . Somatostatin analogues have been radiolabelled with diagnostic radionuclides for imaging and tumour localisation as well as with particle emitters for targeted radionuclide therapy. Labelling has been performed with the γ-emitters 99m Tc [2] [3] [4] , 111 In [5, 6] and 67 Ga [7] , with the positron emitters 11 C [8] , [9] and 64 Cu [10] , and with particle emitters such as 90 Y [11] [12] [13] [14] , 177 Lu [15] and 213 Bi [16] . [ 111 In-DTPA]-octreotide (Octreoscan) is the first registered radiopeptide and currently the most sensitive method for staging of neuroendocrine tumours [17] .
Currently, the metallic positron emitter 68 Ga is of great interest [18] because of its suitable radiophysical properties; its positron yield is high, with 89% of all disintegrations. Its half-life of 68 min matches the pharmacokinetics of many peptides and other small molecules owing to a fast blood clearance, quick diffusion and target localisation. In addition, and of major importance, is the fact that it can be produced from a 68 Ge/ 68 Ga generator. Especially attractive is the long half-life of 270.8 days of the parent 68 Ge, which allows use of the generator for up to 1 year or even longer. A version of this generator is now commercially available, and this is strongly motivating radiopharmacists to develop new radiogallium-based radiopharmaceuticals.
We have been interested in designing peptide-chelator conjugates for labelling with 67, 68 Ga, in particular those based on somatostatin analogues. We used and compared different chelators such as desferrioxamine [7] , NOTAGA (1,4,7-triazacyclononane,1-glutaric acid, 4,7-acetic acid) [19] and DOTA (1,4,7,10-tetraazacyclododecane,1,4,7,10-tetraacetic acid) [20, 21] [20, 21] . These very promising preclinical data prompted several research groups to study [ 68 Ga -DOTA]-TOC in patients with somatostatin receptor-positive tumours [22] [23] [24] [25] [26] [27] . The Bad Berka group has almost 2 years' experience employing 68 Ga-DOTA-octapeptides in a variety of somatostatin receptor-positive tumour patients, mainly gastroenteropancreatic (GEP) tumours [28, 29] . In addition, first promising results have been reported [30, 31] Ga -DOTA]-TATE) was recently used in a patient with paraganglioma [32] .
The main purpose of this work was to study the hypothesis that the influence of radiogallium on pharmacological parameters such as receptor binding affinity, rate of internalisation, tumour uptake etc. may be operative in new DOTA-octapeptides ("third-generation somatostatin analogues"). The latter differ from DOTA-TOC by virtue of an improved somatostatin receptor subtype profile [33, 34] . In PET these new radiopharmaceuticals may have the potential to target a wider range of tumours and to detect more lesions in an individual patient. Therefore we determined the affinity profiles with regard to hsst1-5 of 68/nat Ga-DOTA-octapeptides and compared them with those of 111/nat In-DOTA-octapeptides (or in some cases 177/nat Luand 90/nat Y-DOTA-octapeptides). We also studied the rate of internalisation into sst2,3,5-expressing cell lines and the biodistribution in a rat tumour model (AR4-2J). In addition, we present first PET/CT studies using [ 68 Ga -DOTA]-NOC in comparison to [ 68 Ga -DOTA]-TATE.
Materials and methods
All chemicals, including Fmoc(9-fluorenylmethoxycarbonyl)-protected amino acids, were obtained from commercial sources and used without further purification. Tritylchloride-resin was obtained from PepChem (Tübin-gen, Germany). 67 GaCl 3 and 111 InCl 3 were from Mallinckrodt Medical (Petten, The Netherlands). The prochelator DOTA(tBu) 3 was synthesised according to Heppeler et al. [20] . The reactive side chains of the amino acids were masked with one of the following groups: Cys, acetamidomethyl; Lys, t-butoxycarbonyl; Thr, t-butyl; Trp, t-butoxycarbonyl. Analytical reversed-phase high-performance liquid chromatography (RP-HPLC) was carried out on a Hewlett Packard 1050 HPLC system equipped with a multiwavelength detector and a flow-through Berthold LB506C1 γ-detector. Preparative HPLC was done on a Bischof HPLC-system (Metrohm AG, Switzerland) with HPLC-pumps 2250 and a Lambda 1010 UV-detector. CC250/4 Nucleosil 120-3C18 columns from MachereyNagel were used for analytical HPLC and a VP250/21 Nucleosil 200-5C15 column for preparative HPLC. The gradient systems consisted of mixtures of acetonitrile and water with 0.1% trifluoroacetic acid. Quantitative γ-counting was performed on a COBRA 5003 γ-system well counter from Packard Instrument Company (Switzerland).
Electrospray ionisation-mass spectrometry (ESI-MS) was carried out with a Finnigan SSQ 7000 spectrometer (Bremen, Germany).
Determination of lipophilicity
The octanol-water partition coefficients were determined using the shake flask method. Both solvents (aqueous and octanol) were presaturated with each other by shaking them in contact for hours. To a solution of 100 nmol/l radiolabelled peptide in 500 μl PBS (pH 7.4), 500 μl of octanol was added (n=5). The mixtures were vigorously shaken for 1 h to reach equilibrium. After equilibration, the mixtures were centrifuged (10 min at 2,000 rpm) to achieve good separation. The activity concentrations in 100-μl samples of both the aqueous and the organic phase were measured in a γ-counter. The partition coefficient (log D) was calculated from the formula: log D ¼ log 10 counts in octanol layer=counts in aqueous layer ð Þ
Synthesis
The peptide-chelator conjugates were synthesised by standard Fmoc-solid phase synthesis [34] on tritylchloride resin (substitution 0.8 mmol/g) on a Rink Engineering peptide synthesiser Switch 24 (RinkCombichem Technologies, Bubendorf, Switzerland) according to the general procedure described previously [33] , affording compounds included in Fig. 1 68 Ga. The generator eluate was preconcentrated and purified from potential metallic impurities on a micro-chromatography cation exchange column (50W-X8, <400 mesh, Bio-Rad AG, Munich, Germany). The activities were eluted with 98% acetone/0.05 mol/ l HCl (400 μl). This was added to 4 ml H 2 O containing 10 nmol DOTA-NOC and heated at 100°C for 10 min, leading to a radiochemical yield >95%. The mixture was subject to purification using Sep-Pak C18 cartridge, which was washed with 5 ml H 2 O, followed by 0.5 ml of ethanol diluted in 5 ml of isotonic saline. After sterility filtration, quality control was performed using HPLC and thin-layer chromatography. [ Determination of somatostatin receptor affinity profiles CHO-K1 and CCL39 cells stably expressing human sst1-5 (hsst1-5) were grown as described previously [35] . All culture reagents were supplied by GIBCO/BRL and Life Technologies (Grand Island, NY). Cell membrane pellets were prepared and receptor autoradiography was performed on pellet sections (mounted on microscope slides), as described in detail previously [35] . ).
Cell culture, radioligand internalisation and cellular retention studies
The AR4-2J cell line was maintained by serial passage in mono-layers in Dulbecco's Modified Eagle's Medium Fig. 1 Structural formulae of the peptides studied (DMEM), supplemented with 10% fetal bovine serum, amino acids, vitamins and penicillin-streptomycin, in a humidified 5% CO 2 atmosphere at 37°C. Human embryonic kidney (HEK) 293 cells stably expressing rat sst2, sst3 and sst5 receptors (a gift from Dr. S. Schulz, Magdeburg, Germany) [36] were grown in DMEM supplemented with 10% fetal bovine serum, penicillin-streptomycin and G418 (500 μg/ml) in a humidified 5% CO 2 atmosphere at 37°C. Cell numbers were counted under the microscope with a Neubauer counting chamber. For all cell experiments, the cells were seeded at a density of 0.8-1.1 million cells/well in six-well plates and incubated overnight with internalisation buffer to obtain a good cell adherence. The loss of cells during the internalisation experiments was below 10%. When different radiolabelled peptides were compared in cell experiments, the same cell suspension-containing plates were used. Furthermore, the internalisation rate was linearly corrected to 1 million cells/well. Medium was removed from the six-well plates and cells were washed once with 2 ml of internalisation buffer (DMEM, 1% fetal bovine serum, amino acids and vitamins, pH 7.4). Furthermore, 1.5 ml internalisation buffer was added to each well and incubated at 37°C for about 1 h. Thereafter approximately 500,000 cpm or 0.02 MBq/well 67 Ga/Ga III -and 111 In/In III -labelled peptides (2.5 pmol/well) to a final concentration of 1.67 nmol/l were added to the medium and the cells were incubated in triplicate at 37°C for the indicated time periods. To determine non-specific membrane binding and internalisation, cells were incubated with the radioligand in the presence of 1 μmol/l [In III -DOTA]-NOC. Cellular uptake was stopped by removing the medium from the cells and by washing twice with 1 ml ice-cold PBS. An acid wash for 10 min with a glycine buffer pH 2.8 on ice was also performed twice. This procedure was performed to distinguish between membrane-bound (acid-releasable) and internalised (acid-resistant) radioligand. Finally, the cells were treated with 1 mol/l NaOH. The culture medium, the receptor-bound and the internalised fraction were measured radiometrically in a γ-counter (Packard, Cobra II).
For cellular retention studies, HEK-sst2 cells (1 million) were incubated with 2.5 pmol/well (1.67 nmol/l) [ 111 In/ In III ]-or [ 67 Ga/Ga III ]-labelled DOTA-NOC, DOTA-BOC or DOTA-TOC for 120 min, respectively, then the medium was removed and the wells were washed twice with 1 ml ice-cold PBS. In each experiment an acid wash for 10 min on ice with a glycine buffer of pH 2.8 was performed twice to remove the receptor-bound ligand. Cells were then incubated again at 37°C with fresh internalisation buffer (DMEM containing 1% fetal bovine serum, pH 7.4). After different time points the external medium was removed for quantification of radioactivity in a γ-counter and replaced with fresh 37°C medium. The cells were solubilised in 1 mol/l NaOH and removed, and the internalised radioactivity was quantified in a γ-counter. The externalised fraction was expressed as percentage of the total internalised amount per 1 million cells.
Biodistribution studies in tumour-bearing rats Animals were kept, treated and cared for in compliance with the guidelines of the Swiss regulations (approval #789). Five-week-old male Lewis rats were implanted subcutaneously with 10-12 million AR4-2J cells freshly suspended in sterile PBS. Fourteen days after inoculation, the rats showed solid palpable tumour masses (tumour weight 0.4-0.7 g) and were used for the experiments. Rats were injected under ether anaesthesia with 2- Ga -DOTA]-TOC, in 0.05 ml NaCl solution 0.9% into the femoral vein. At 4 h and 24 h after injection rats were sacrificed under ether anaesthesia. Organs and blood were collected and the radioactivity in these samples was determined using a γ-counter.
In order to determine the non-specific uptake of the radiopeptides, rats were injected with 50 μg [In III -DOTA]-NOC in 0.05 ml NaCl solution 0.9% as a co-injection with the radioligand.
Patient study
Whole-body PET/CT scan was performed on a Siemens biograph duo (Siemens, Germany). The 65-year-old male patient was operated on owing to a neuroendocrine pancreatic carcinoma (immunohistochemical staining positive for chromogranin and CD56) 6 months before the PET/CT study by left pancreatectomy, splenectomy and resection of a single liver metastasis in the left lobe (segment SII). Postoperative treatment with octreotide (Sandostatin LAR 20 mg/month) was started and stopped 4 weeks before the first PET/CT study.
Statistical methods
To compare differences between the radiopeptides, Student's t test was used. P values <0.05 were considered significant.
Results
The peptides conjugated to DOTA presented in Fig. 1 were synthesised by solid phase synthesis [33, 35] . Their complexes were characterised by analytical HPLC and ESI-MS. Radioligands were obtained at specific activities of >37 GBq/μmol and a radiochemical purity of >97%.
Receptor binding and affinity profiles III -DOTA-octapeptides were higher (affinity was lower) than on hsst2. In addition and conversely to the hsst2 situation, the binding affinity of Ga III -complexed peptides was lower than that of the other metallopeptides. On hsst4 the affinity is very low for most of the peptides, with a few exceptions.
Again Ga -DOTA]-NOC was also found in most other somatostatin receptor-positive organs such as the adrenals, the bowel and the pituitary. The specificity of uptake in these organs was again demonstrated by blocking of the organs with excess cold peptide. Co-injection of 100 μg DOTA-NOC efficiently blocked (by >93%) the uptake in all of these organs except the bowel, where the blocking was by 81%. No blocking was found for the liver, the kidneys or the spleen.
The liver uptake of [ Fig. 3 an example is given of a patient with a neuroendocrine pancreatic carcinoma. The patient was scanned with [ 68 Ga -DOTA]-NOC (Fig. 3a) , [ 68 Ga-DOTA]-TATE (Fig. 3b) and [ 18 F]fluorodeoxyglucose (FDG) (Fig. 3d) . Eighty-five MBq [ 68 Ga -DOTA]-NOC was injected. The scan, performed at 140 min p.i., revealed very intense uptake (SUV max 152) in a left retrocrural lymph node metastasis (Fig. 3a) as well as in a parapancreatic lymph node (SUV 9.2) and in a very small lesion near the processus uncinatus of the pancreas (SUV 6.8). In addition, a small (10 mm) liver metastasis in the right inferior liver segment (S VI) was detected (SUV 11.6) (Fig. 3c) , which had also been described in an MRI study.
The second PET/CT was performed 3 weeks later after i.v. injection of 130 MBq of [ 68 Ga -DOTA]-TATE, starting the acquisition 85 min p.i. Again, very high uptake (SUV max 103) was seen in the retrocrural metastasis (Fig. 3b) , but no other lesions were detectable (Fig. 3c) .
There was no increased glucose metabolism (normal [ 18 F]FDG PET/CT) in any of the lesions shown by the receptor PET/CT studies (Fig. 3d) .
Discussion
The use of 68 Ga in nuclear oncology is becoming of increasing interest as it is a generator-produced, easily available positron emitter. 68 Ga has a physical half-life of 68 min, which is compatible with the pharmacokinetics of most radiopharmaceuticals of low molecular weight such as antibody fragments, peptides, aptamers, oligonucleotides, etc. [37, 38] . 68 Ga decays to 89% by positron emission and to 11% via electron capture. The parent isotope 68 Ge has a very long half-life of 270.8 days, which allows routine manufacture and shipment, while the Ga -DOTA]-TOC a Blocked with 0.1 mg DOTA-NOC as a co-injection with the radiopeptide chemical properties of Ge(IV) and Ga(III) are sufficiently different to allow several different methods of efficient separation.
A particularly fascinating group of 68 Ga-based radiopharmaceuticals are chelator-modified regulatory peptides that, owing to their small size, have ideal pharmacokinetics compatible with the short-lived 68 Ga. Particularly somatostatin derivatives such as [ nat Ga -DOTA]-TOC and [ nat Ga-DOTA]-TATE show outstanding binding affinity to sst2 that is a factor of 4-8 higher compared with the corresponding yttrium or indium derivatives [5, 20, 35] . The higher binding affinity resulted in significantly higher tumour uptake in a tumour-bearing mouse model [20, 21] . These positive preclinical results have prompted several Fig. 3 Comparison between 68 Ga-DOTA-NOC and 68 Ga-DOTA-TATE in the same patient (with a metastatic neuroendocrine pancreatic tumour), along with an [ [22] [23] [24] [25] [26] [27] 32] .
We have recently reported that [ 111 In-DOTA]-NOC may be a promising candidate for somatostatin receptor-positive tumour targeting because it recognises three somatostatin receptor subtypes with high affinity and may therefore target a broader range of tumours. Indeed, some preliminary results suggest that this new radiopeptide, if labelled with 68 Ga, locates more metastases than the second-generation radiopeptides [30, [39] [40] [41] , indicating that these new peptides are also pharmacologically superior compared with their 111 In congeners. We designed a study to support these early clinical observations with firm preclinical pharmacological data using the 68 Ga congener, 67 Ga. A general trend was seen in regard to the binding affinity and the affinity profile of the Ga III vs M III -DOTA-peptides On hsst3 there was a tendency in the opposite direction: the affinities of the Ga III -complexed peptides were two-to fivefold lower. On hsst5 no clear tendency was obvious. None of the peptides has affinity to sst1 but surprisingly some emerging hsst4 affinity can be seen, especially when complexed with Ga III . We do not yet know which structural features are responsible for the latter.
A more striking advantage of the 67 Ga-DOTA-peptides becomes evident upon studying the rate of internalisation into different cell lines. In sst2-expressing cells all 67 Galabelled peptides showed high and specific internalisation with a significantly higher rate compared with the 111 In congeners. The difference between the two radionuclides became more striking when the internalisation was studied in HEK-sst2 cells, which express a higher number of receptors compared with AR4-2J cells.
In [21] . The present data, however, showed a significant difference between the two radiopeptides. The internalisation into HEK-sst3 was comparatively low with no uptake of [ 67 Ga/ 111 In-DOTA]-TOC, as expected, and paralleling the very low binding affinity of these two peptides to sst3. In contrast to the sst2 data, the general tendency was for the 111 In-labelled peptides to show more efficient internalisation into sst3, with the exception of [ 67 Ga-DOTA]-and 111 In-DOTA]-NOC, which internalised at an equal rate, not corresponding to the fivefold difference in binding affinity.
None of the radiopeptides internalises into sst5, which most likely is an intrinsic property of this receptor [42] . These in vitro pharmacological data indicate that [ 67 Ga-DOTA]-BOC is the most promising radiopeptide to develop. However, as it showed some instability during labelling, we decided to study [ 67 Ga-DOTA]-NOC in our tumour model. The analysis of the biodistribution at 4 and 24 h showed a significantly higher tumour uptake of [ 67 Ga-DOTA]-NOC compared with [ 111 In-DOTA]-NOC. We hypothesise that the more rapid internalisation kinetics measured in vitro contributes to the increased in vivo uptake. We recently found that in a group of six somatostatin-based octapeptides labelled with 99m Tc and 111 In, a good correlation indeed existed between tumour and pancreas uptake in vivo and the rate of internalisation into the AR4-2J cell line in vitro [4] . The uptake in other somatostatin receptor-positive tissues, such as the adrenals, the stomach and the bowel, follows this trend.
The potential of an imaging probe depends, among other parameters, on the target-to-non-target ratios, especially the tumour-to-blood ratio. All three radiopeptides showed a very high tumour-to-blood ratio, [ 67 Ga-DOTA]-NOC having the highest among them. In addition, the tumour-tokidney ratio of 4.5 at 4 h and 5.1 at 24 h is, to the best of our knowledge, the highest of any radiometal-labelled peptide reported so far. On the other hand, the tumour-toliver ratio was clearly lowest for [ 67 An interesting finding from this study is that the radiometal indeed influences the pharmacological properties of the radiopeptides; this earlier finding [21, 35] can be extended to the new generation of somatostatin-based radiopeptides. Labelling with 67/ 68 Ga results in peptides that are superior to those labelled with 111 In, 90 Y or 177 Lu. We have explained this difference by a difference in the coordination number and geometry of the various radiometal complexes [20] . The model peptide Ga III -DOTA-DPheNH 2 showed a cis-pseudo-octahedral geometry without the coordination of the amide linkage and the corresponding trans carboxy methyl group, whereas the Y III complex is octacoordinate including the amide carboxy oxygen and the carboxymethyl group. The complex geometry is a somewhat distorted square antiprism [20] . The non-involved amide linkage of the Ga III complex consequently offers more flexibility, the free arm acting as a spacer between peptide and chelate. This may lead to the higher binding affinity on hsst2 whereas the free carboxylate group may favour kidney excretion.
In summary, these data suggest that most, if not all, 68 Ga-labelled second-and third-generation somatostatinbased radiopeptides show superior properties in imaging somatostatin receptor-positive tumours compared with firstgeneration somatostatin-based radiopeptides. This is due to superior pharmacological properties on hsst2, which is the most densely and frequently expressed receptor subtype. Despite some loss in hsst3 and hsst5 affinity, the radio- 68 Ge/ 68 Ga generator, these tracers may be very cost effective, sensitive and readily available imaging agents. Furthermore, they cause low radiation doses to patients compared with existing tracers and their 111 Inlabelled congeners [31] . Along with 64 Cu-labelled radiopharmaceuticals [43] [44] [45] , 68 Ga-labelled compounds are a fast-growing area of research which benefits from the availability of a commercial generator. 
